[Federal Register Volume 68, Number 39 (Thursday, February 27, 2003)]
[Notices]
[Pages 9088-9089]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-4599]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Cooperative Research and Development Agreement

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC) National 
Immunization Program (NIP) is seeking a Cooperative Research and 
Development Agreement (CRADA) partner for collaboration in the 
development of a Vaccine Management Software (VACMAN) dynamic link 
library (DLL) component to interface with immunization information 
systems. The current DLL is compatible to VACMAN version 2.6x and will 
not be compatible when VACMAN is upgraded to version 3.
    Because CRADAs are designed to facilitate the development of 
scientific and technological knowledge into useful, marketable 
products, a great deal of freedom is given to Federal agencies in 
implementing collaborative research. The CDC may accept staff, 
facilities, equipment, supplies, and money from the other participants 
in a CRADA; CDC may provide staff, facilities, equipment, and supplies 
to the project. CDC may not provide funds to the other participants in 
a CRADA. This opportunity is available until 30 days after publication 
of this notice in the Federal Register. Respondents may be provided a 
longer period of time to furnish additional information if CDC finds 
this necessary.

FOR FURTHER INFORMATION CONTACT: 
    Technical: Terry Boyd, Data Management Division, National 
Immunization Program, Centers for Disease Control and Prevention (CDC), 
1600 Clifton Rd., NE., Mailstop E-62, Atlanta, GA 30333, telephone 
(404) 639-8584.
    Business: Janet Kelly, Data Management Division, National 
Immunization Program, Centers for Disease Control and Prevention (CDC), 
1600 Clifton Rd., NE., Mailstop E-62, Atlanta, GA 30333, telephone 
(404) 639-8735.

SUPPLEMENTARY INFORMATION: The VACMAN application was developed by the 
CDC NIP and is used by CDC Immunization Grant programs to purchase 
vaccines through a Vaccine

[[Page 9089]]

Ordering and Distribution System. The VACMAN DLL interface component 
allows immunization information systems to interface with VACMAN.
    The CDC/NIP Development Team will work with respondent to develop 
and promote a product that will support VACMAN connectivity with 
immunization information systems and other applications that might 
exist on different operating systems. Respondent will be given access 
to VACMAN 3 database specifications and business rules. Respondent will 
maintain the code such that it is constantly kept updated accordingly 
as changes in the VACMAN product occurs. CDC/NIP requires the use of 
the source code and free distribution rights for the object code, which 
may include vendors, to ensure all available products can interact with 
VACMAN consistently and that all Grant programs have the opportunity to 
integrate VACMAN with their other processes for properly managing their 
vaccines.
    Applicant submissions will be judged according to the following 
criteria:
    1. Evidence of expertise in software development and supporting 
data (e.g., resumes) of qualifications for the principle investigator 
who would be involved in the CRADA.
    2. Specific operating systems and development languages proposed 
for development of the DLL.
    3. Evidence of commitment for development to release to Grant 
programs, including vendors, the compiled components along with all 
appropriate documentation such as Application Program Interface 
documentation.
    With respect to Government Intellectual Property (IP) rights to any 
invention not made solely by a CRADA partner's employees for which a 
patent or other IP application is filed, CDC has the authority to grant 
to the CRADA partner an exclusive option to elect an exclusive or 
nonexclusive commercialization license. This option does not apply to 
inventions conceived prior to the effective date of a CRADA that are 
reduced to practice under the CRADA, if prior to that reduction to 
practice, CDC has filed a patent application on the invention and has 
licensed it or offered to license it to a third party. The terms of the 
license will fairly reflect the nature of the invention, the relative 
contributions of the Parties to the invention and the CRADA, the risks 
incurred by the CRADA partner and the costs of subsequent research and 
development needed to bring the invention to the marketplace. The field 
of use of the license will be commensurate with the scope of the 
Research Plan.
    This CRADA is proposed and implemented under the 1986 Federal 
Technology Transfer Act: Public Law 99-502, as amended.
    The responses must be made to: Lisa Blake-DiSpigna, Technology 
Development Coordinator, National Center for Infectious Diseases, 
Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE., 
Mailstop C-19, Atlanta, GA 30333.

    Dated: February 21, 2003.
Joseph R. Carter,
Associate Director for Management and Operations, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 03-4599 Filed 2-26-03; 8:45 am]
BILLING CODE 4163-18-P